May 27, 2022 8:51am EDT Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference
May 06, 2022 11:17am EDT Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient
May 02, 2022 10:02am EDT Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim
Apr 27, 2022 9:49am EDT Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022
Apr 21, 2022 7:59am EDT Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics
Apr 20, 2022 8:01am EDT Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study
Apr 19, 2022 7:22am EDT Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group
Apr 06, 2022 8:46am EDT Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label
